|
    GILD U.S.: Nasdaq

    Gilead Sciences Inc.

    GILDUS
    After Hours
    Back To Top
    Last Updated: Mar 23, 2020 4:25 p.m. EDT Delayed quote

    $ 73.88

    1.27 1.75%
    After Hours Volume: 400.9K
    Health Care/Life Sciences 0.03%
    Close Chg Chg %
    $72.61 -0.65 -0.89% -0.65 -0.89%
    Advanced Charting
    • $
    • %
    • Vol
    Advanced Charting
    106.0% vs Avg.
    Volume: 19.1M 65 Day Avg. - 18M
    Open: 75.30
    Close: 72.61
    68.86 Day Low/High 75.30
    Day Range
    60.89 52 Week Low/High 85.97

    Your Watchlist

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    7073彩票注册Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    Key Data

    • Open $75.30
    • Day Range 68.86 - 75.30
    • 52 Week Range 60.89 - 85.97
    • Market Cap $92.57B
    • Shares Outstanding 1.26B
    • Public Float 1.26B
    • Beta 0.75
    • Rev. per Employee $2.02M
    • P/E Ratio 17.25
    • EPS $4.21
    • Yield 3.75%
    • Dividend $0.68
    • Ex-Dividend Date Mar 12, 2020
    • Short Interest 23.76M 02/28/20
    • % of Float Shorted 1.89%
    • Average Volume 18M

    Performance

    5 Day
    • 5.38%
    1 Month
    • -0.40%
    3 Month
    • 8.78%
    YTD
    • 11.74%
    1 Year
    • 13.83%

    Recent News

    • MarketWatch
    • WSJ
    Read full story

    These 16 companies are working on coronavirus treatments or vaccines — here’s where things stand

    Read full story

    You can be ‘practically stealing’ quality stocks now, according to Jefferies

    Gilead Sciences, 'flooded' by demand for remdesivir, halts compassionate use

    Gilead Sciences Inc. said soaring demand for remdesivir, its experimental COVID-19 treatment, through individual compassionate use requests has prompted the drugmaker to halt those requests while it sets up a new process. Gilead is creating expanded use programs for patients undergoing treatment for COVID-19. In the U.S., patients primarily have access to investigational drugs if they are participating in a clinical trial for that therapy or have applied for compassionate use, which is a regulatory pathway that allows people with life-threatening conditions to apply for access to a drug that has not yet been approved by the Food and Drug Administration. "In recent weeks, there has been an exponential increase in compassionate use requests for emergency access to remdesivir" as the disease has spread in Europe and the U.S., Gilead said. "This has flooded an emergency treatment access system that was set up for very limited access to investigational medicines and never intended for use in response to a pandemic." It said it has provided the drug to several hundred patients with COVID-19 in Europe, Japan, and the U.S. The drugmaker is currently conducting two Phase 3 trials and one Phase 2 trial examining the safety and efficacy of remdesivir as a treatment for COVID-19. Shares of Gilead were down 5% in trading on Monday. Year-to-date, the company's stock is up 6%, compared with the S&P 500 , which has dropped 28%.

    Gilead Stops Accepting Emergency Applications for Covid-19 Drug Remdesivir

    The biotech company says it received “overwhelming demand” for the drug in the past few days.

    Read full story

    What Apple, Microsoft, GE and other U.S. companies are saying about the coronavirus outbreak

    Read full story

    Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness

    Read full story

    Good news for the stock market would be any potential treatment against the coronavirus

    President Praises Antiviral Treatments in FDA News Conference

    Trump said that he was “very excited” about chloroquine, an inexpensive generic product used for decades against malaria and arthritis. It isn’t tested or approved to treat Covid-19.

    Read full story

    Think twice before investing in biotech companies working on coronavirus treatments — ‘the odds of picking a winner are low’

    Read full story

    Here’s one analyst’s take on the coronavirus drugs for today and the future

    Read full story

    How long will coronavirus last? It depends — but ‘prepare yourself for a long ride’

    Regeneron’s CEO Says We Could Have a Covid-19 Treatment ‘Quickly’

    “This could really slow down the number of people who needed really intensive respiratory therapy. This could go fairly quickly,” CEO Leonard Schleifer said in an interview with Barron’s.

    10 Quality 7073彩票注册 Priced at a ‘Steal’ Right Now

    7073彩票注册It offered a list of stocks spanning all sectors that investors would want to own across a business cycle, despite potential near-term drawbacks.

    21 7073彩票注册 to Buy for a Coronavirus Economy

    7073彩票注册7073彩票注册 such as Clorox, Netflix, and Zoom Video stand to benefit after the acute phase of the outbreak passes, Bespoke Investment Group says.

    The Dow Is Down 816 Points as Coronavirus Worries Remain Front and Center

    The Dow Jones Industrial Average, S&P, and Nasdaq Composite all fell again on Wednesday as the coronavirus outbreak continued to drag on markets.

    Read full story

    Investors trust Trump’s two ‘magic words,’ and now it’s time to nibble on stocks

    What Got Hammered: A Sector-by-Sector Look at Key Industries

    It was a brutal Monday on Wall Street—it got so bad, trading in the S&P 500 was halted. Many sectors bounced back on Tuesday, but will the recovery continue?

    Coronavirus Is Bad — and Good — for Biotech 7073彩票注册

    Clinical trials and regulatory reviews may slow amid the outbreak’s disruption. New drug launches could suffer.

    Two Companies Are Making Progress on Coronavirus Treatments. The 7073彩票注册 Aren’t Responding.

    Gilead Sciencesand Regeneron Pharmaceuticals are both making progress in developing treatments for coronavirus.

    The Drugs That Could Cure Coronavirus – and the Companies That Make Them

    7073彩票注册One analyst has some out-of-the box ideas about drugs already on the market from Gilead Sciences, AbbieVie, and GlaxoSmithKline.

    Clinical trials for experimental drugs often have high financial stakes. Coming trial results for possible Covid-19 treatments are in a category of their own.

    on The Wall Street Journal

    Concern is high about the deadly virus behind a fast-growing global outbreak. Here is what health officials know so far.

    on The Wall Street Journal

    7073彩票注册Drug companies will save lives, even as Bernie Sanders is denouncing them.

    on The Wall Street Journal

    7073彩票注册President Trump said he is directing the FDA to expedite testing and possible broader use of some investigational medicines to help treat coronavirus patients.

    on The Wall Street Journal

    Scientists trying to develop treatments for the new coronavirus have struggled to get a hold of recovered patients’ blood samples, which contain the building blocks needed to create new medicines.

    on The Wall Street Journal

    The antiviral drug remdesivir appeared to have an effect in American cruise passengers treated for the novel coronavirus in Japan, although data are limited, according to a doctor sent to Tokyo by the U.S. government.

    on The Wall Street Journal

    7073彩票注册From gold to tech to Warren Buffett’s next buys, here are pockets of the market to follow closely in the weeks ahead.

    on The Wall Street Journal

    The antiviral drug remdesivir appeared to have an effect in American cruise passengers treated for the novel coronavirus in Japan, although data are limited, according to a doctor sent to Tokyo by the U.S. government.

    on The Wall Street Journal

    7073彩票注册What’s known about the virus, how to protect yourself, who pays for testing and treatment—and how worried you should be.

    on The Wall Street Journal

    Numerous projects are under way to find cures or treatments—but don’t expect an answer anytime soon.

    on The Wall Street Journal

    The Dow industrials fell about 2,300 points, the index’s worst day since the 1987 crash, as fear over the impact of coronavirus roiled markets around the world despite actions from the Federal Reserve and European Central Bank.

    on The Wall Street Journal

    7073彩票注册Drugmakers Regeneron Pharmaceuticals Inc. and Sanofi SA are racing to launch clinical trials exploring whether their arthritis drug could treat symptoms of novel coronavirus infections.

    on The Wall Street Journal

    Companies racing to find treatments for the novel coronavirus, which has infected close to 100,000 people, are turning to artificial intelligence to speed up their drug-discovery efforts.

    on The Wall Street Journal

    Japan is racing to test a homegrown drug against the novel coronavirus despite doubts about its efficacy and its potential for causing birth defects.

    on The Wall Street Journal

    7073彩票注册The Japanese drugmaker says it is trying to develop a drug to treat people infected with the novel coronavirus or at high risk of contracting it.

    on The Wall Street Journal

    And markets have historically been quick to recover from pandemic threats.

    on The Wall Street Journal

    The biopharmaceutical company seeks to deepen its pipeline of cancer drugs with the acquisition and plans to make more deals similar in size and scope.

    on The Wall Street Journal

    Here are seven major companies whose stocks moved on this week’s news.

    on The Wall Street Journal

    Our columnist goes through the numbers on whether this week’s coronavirus market tumble is a buying opportunity—or not.

    on The Wall Street Journal

    Betting on a treatment for Covid-19 isn’t likely to be a cure-all for investor portfolios.

    on The Wall Street Journal

    Recent News

    • Other News
    • Press Releases

    Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults

    on Zacks.com

    25 7073彩票注册 That Are Holding Up Well

    on Seeking Alpha

    7073彩票注册Don’t Forget About 7073彩票注册 to Buy During the Coronavirus Crisis

    on InvestorPlace.com

    7073彩票注册Gilead Stock Flies High With a Potential Coronavirus Treatment

    on InvestorPlace.com

    Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.

    on Zacks.com

    26 Benjamin Graham-inspired stock picks

    on Seeking Alpha

    7073彩票注册Clinical trials for experimental drugs often have high financial stakes. Coming trial results for possible Covid-19 treatments are in a category of their own.

    on The Wall Street Journal

    7073彩票注册Gilead suspends access to remdesivir amid flood of requests

    on Seeking Alpha

    Concern is high about the deadly virus behind a fast-growing global outbreak. Here is what health officials know so far.

    on The Wall Street Journal

    7073彩票注册It goes without saying that 2020 has been a very challenging year. The 11-year old stock raging bull stock market over the course of a month has died and turned into a roaring bear market with the major equity indexes down over 30% so far from the top. The coronavirus is mostly to blame, along [ ]

    on 247WallSt.com

    Dividend Challenger Highlights: Week Of March 22

    on Seeking Alpha

    Week 13 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

    on Seeking Alpha

    Coronavirus Pandemic Requires Patient Investing And A Focused Portfolio

    on Seeking Alpha

    The Secular Bull Is Bruised But, Similar To The Period After The 1987 Crash, Is Alive And Well

    on Seeking Alpha

    7073彩票注册After falling for three straight years on declining sales of hepatitis C drugs, Gilead Sciences’ (GILD) revenues finally seemed to bottom last year, ...[...]

    on SmarterAnalyst

    7073彩票注册The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.

    on Zacks.com

    7073彩票注册24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this novel coronavirus. Here's how they fared as the week wound down.

    on 247WallSt.com

    7073彩票注册3 of the Strongest 7073彩票注册 to Buy

    on InvestorPlace.com

    7073彩票注册Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.

    on Zacks.com

    Tracking John Rogers' Ariel Investments Portfolio - Q4 2019 Update

    on Seeking Alpha

    Lifshitz Law Firm, P.C. Announces Investigation of Forty Seven, Inc., Hexcel Corporation, Legg Mason, Inc., and Mobile Mini, Inc.

    7073彩票注册Lifshitz Law Firm, P.C. Announces Investigation of Forty Seven, Inc., Hexcel Corporation, Legg Mason, Inc., and Mobile Mini, Inc.

    on GlobeNewswire

    Lifshitz Law Firm, P.C. Announces Investigation of Forty Seven, Inc., Hexcel Corporation, Legg Mason, Inc., and Mobile Mini, Inc.

    Lifshitz Law Firm, P.C. Announces Investigation of Forty Seven, Inc., Hexcel Corporation, Legg Mason, Inc., and Mobile Mini, Inc.

    on GlobeNewswire

    Sterile Injectables Market Report 2018: Rising Impressive Business Opportunities Analysis Forecast By 2023

    Sterile Injectables Market Report 2018: Rising Impressive Business Opportunities Analysis Forecast By 2023

    on AmericaNewsHour

    Biotechs and Big Pharma in a Race Against Time Battling Global Health Crisis

    Biotechs and Big Pharma in a Race Against Time Battling Global Health Crisis

    on Financial News Media

    Biotechs and Big Pharma in a Race Against Time Battling Global Health Crisis

    7073彩票注册Biotechs and Big Pharma in a Race Against Time Battling Global Health Crisis

    on PR Newswire - PRF

    Cervical Cancer Drug Market 2020 Is Expected To Gain Massive Growth | Novartis AG, Hetero, Alnylam Pharmaceuticals, Inc, Biocon

    7073彩票注册Cervical Cancer Drug Market 2020 Is Expected To Gain Massive Growth | Novartis AG, Hetero, Alnylam Pharmaceuticals, Inc, Biocon

    on The Express Wire

    Gilead Sciences Wrestles With Soaring Demand

    7073彩票注册Gilead Sciences Wrestles With Soaring Demand

    on Baystreet.ca

    Global Nanopharmaceuticals Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025

    7073彩票注册Global Nanopharmaceuticals Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025

    on CDN Newswire

    DNA Forensics Market - 2020 Trends, Size, Share, Growth Rate, New Technologies, Key Country Analysis, Regional Outlook And Global Forecast To 2026

    7073彩票注册DNA Forensics Market - 2020 Trends, Size, Share, Growth Rate, New Technologies, Key Country Analysis, Regional Outlook And Global Forecast To 2026

    on The Express Wire

    Anti-infective Agents Market Trends and Key Players: Pfizer Abbott Laboratories, Gilead Sciences, Bristol-Myers Squibb Co., Merck & Co., Bayer Healthcare AG, AstraZeneca Plc.

    7073彩票注册Anti-infective Agents Market Trends and Key Players: Pfizer Abbott Laboratories, Gilead Sciences, Bristol-Myers Squibb Co., Merck & Co., Bayer Healthcare AG, AstraZeneca Plc.

    on Xherald

    HGH Biosimilars Market 2020 Driven Increasing Demand and Opportunity Assessment, 2020-2024

    7073彩票注册HGH Biosimilars Market 2020 Driven Increasing Demand and Opportunity Assessment, 2020-2024

    on The Express Wire

    Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

    7073彩票注册Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

    on GlobeNewswire

    Humanigen Planning Phase III Study of Coronavirus Treatment

    7073彩票注册Humanigen Planning Phase III Study of Coronavirus Treatment

    on ACCESSWIRE

    2019 Competition News Global Antiviral Drugs Market Size, Top Players, Trends and Forecast to 2025

    2019 Competition News Global Antiviral Drugs Market Size, Top Players, Trends and Forecast to 2025

    on AmericaNewsHour

    Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials

    Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials

    on BusinessWire - BZX

    Global AIDS Related Cancer Market 2019 | Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast to 2025

    Global AIDS Related Cancer Market 2019 | Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast to 2025

    on AmericaNewsHour

    Thinking about buying stock in Gilead Sciences, Petmed Express, Tilray, Tonix Pharmaceuticals, or Wix.Com?

    Thinking about buying stock in Gilead Sciences, Petmed Express, Tilray, Tonix Pharmaceuticals, or Wix.Com?

    on PR Newswire - PRF

    Parkinsons Disease Drugs Market 2020 by Technology, Opportunity Analysis and Industry Forecasts 2024

    Parkinsons Disease Drugs Market 2020 by Technology, Opportunity Analysis and Industry Forecasts 2024

    on The Express Wire

    Hepatitis C Treatment Market 2020 Research Provides an In-Depth Analysis on the Future Growth Prospects and Market Trends Adopted by the Competitors

    Hepatitis C Treatment Market 2020 Research Provides an In-Depth Analysis on the Future Growth Prospects and Market Trends Adopted by the Competitors

    on The Express Wire

    Cardiovascular Drugs Market Reach around US$ 92.3 Bn by 2026

    7073彩票注册Cardiovascular Drugs Market Reach around US$ 92.3 Bn by 2026

    on Market Prediction

    Gilead Sciences Inc.

    Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA. (See Full Profile)

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 27 Full Ratings

    Competitors

    Name Chg % Market Cap
    Eli Lilly & Co. -2.74% $117.06B
    Biogen Inc. -3.44% $48.52B
    Johnson & Johnson -7.30% $316.07B
    Vertex Pharmaceuticals Inc. -1.84% $53.41B
    AbbVie Inc. -6.28% $101.8B
    Competitor Data Provided By
    689彩票邀请码 7072彩票开户 7073彩票注册 963彩票开户 7073彩票网址 7073彩票地址 7073彩票登录 66顺彩票app 8炫彩彩票app 677彩票开户